FORM PT (REV 9-20		ATTORNEY'S DOCKET NUMBER					
	TRANSMITTAL LETTER TO THE UNITED STATES 280502000200						
DESIGNATED/ELECTED OFFICE (DO/EO/US) U.S. APPLICATION NO. (If known, see 37 CF)							
CONCERNING A FILING UNDER 35 U.S.C. 371 09/936,887 INTERNATIONAL APPLICATION NO. INTERNATIONAL FILING DATES PRIORITY DATE CLAIMED							
PCT/CA00/00266 13/03/2000 12/03/1999							
TITLE OF INVENTION METHODS AND COMPOSITIONS FOR TREATING LEUKEMIA							
APPLI	CANT(S) FOR DO/EO/US Chaim M. ROIFMAN, et al						
Applica	nt herewith submits to the United States Designated/Elected Office (DO/EO/US) the fo	ollowing items and other information:					
1.	France Comments of the Comment						
2.	This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. This is a SECOND or SUBSEQUENT submission of items concerning a filing 35 U.S.C. 371						
3.	This is a SECOND or SUBSEQUENT submission of items concerning a filing 35 U.S.C. 371 This is an express request to begin national examination procedures (35 U.S.C. 371 (f)). The submission must include items (5), (6), (9) and (21) indicated below.						
4.	The US has been elected by the expiration of 19 months from the priority	date (PCT Article 31).					
5.	A copy of the International Application as filed (35 U.S.C. 371 (c)(2))	2003					
a.	is attached hereto (required only if not communicated by the Internation	7003 onal Bureau).					
b	has been communicated by the International Bureau.						
c.	is not required, as the application was filed in the United States Received	ving Office (RO/US).					
6.	An English language translation of the International Application as filed (35 U.S.C. 371 (c)(2)).					
a.	is attached hereto.						
b	has been previously submitted under 35 U.S.C. 154(d)(4).						
7.	Amendments to the claims of the International Application under PCT Art	ticle 19 (35 U.S.C. 371 (c)(3))					
a.	are attached hereto (required only if not communicated by the Internat	tional Bureau).					
b	have been communicated by the International Bureau.						
c.	have not been made; however, the time limit for making such amendn	nents has NOT expired.					
d	have not been made and will not be made.	·					
8.	An English language translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371 (c)(3)).						
9.	An oath or declaration of the inventor(s) (35 U.S.C. 371 (c)(4)).						
10.	An English language translation of the annexes to the International Prelim Article 36 (35 U.S.C. 371 (c)(5)).	inary Examination Report under PCT					
Items 1	1 to 20 below concern document(s) or information included:	2					
11. x	An Information Disclosure Statement under 37 CFR 1.97 and 1.98.						
12.	An assignment document for recording. A separate cover sheet in compliant	ance with 37 CFR 3.28 and 3.31 is included.					
13.	A FIRST preliminary amendment.						
14.	A SECOND or SUBSEQUENT preliminary amendment.						
15.	A substitute specification.						
16.	A change of power of attorney and/or address letter.						
17.	A computer-readable form of the sequence listing in accordance with PCT Rule 13ter.2 and 35 U.S.C. 1.821 - 1.825.						
18.	A second copy of the published international application under 35 U.S.C. 154(d)(4).						
19.	A second copy of the English language translation of the international application under 35 U.S.C. 154(d)(4).						
20. x							
page 1 of	2						

U.S. APPLICATION NO. (if known,		INTERNATIONAL APPLICAT	ATTORNEY'S DOCKET NUMBER 280502000200					
	ng fees are submitted:	POTICAGO	CALCULATIONS PTQ USE ONLY					
	•		- Separate					
BASIC NATIONAL FEE (37 CFR 1.492 (a) (1) – (5)): Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO and International Search Report not prepared by the EPO or JPO \$1060.00								
	nary examination fee (37 Cl onal Search Report prepare	FR 1.482) not paid to d by the EPO or JPO	\$900.00	2 3 2003 TEH 1600				
International prelimit but international sear	nary examination fee (37 C och fee (37 CFR 1.445(a)(2)	FR 1.482) not paid to USPTO) paid to USPTO	O \$750.00	200				
International preliminary examination fee (37 CFR 1.482) paid to USPTO but all claims did not satisfy provisions of PCT Article 33(1)-(4)\$720.00					0/29			
	nary examination fee (37 Cled provisions of PCT Articles	FR 1.482) paid to USPTO e 33(1)-(4)	.\$100.00					
		SIC FEE AMOUNT =		\$		-		
Surcharge of \$ 20 30 months	·	g the oath or declaration ed priority date (37 CFR 1		\$		*		
CLAIMS	NUMBER FILED	NUMBER EXTRA	RATE					
Total claims	-20 =		X	\$				
Independent claims	-3 = \	11->	x	\$				
MULTIPLE DEPENDE		L OF ABOVE CALCU	HATIONS =	\$ \$	0.00	 		
Applicant claims sr are reduced by ½.		37 CFR 1.27. The fees		\$	0.00			
are reduced by 72.		S	UBTOTAL =	\$	0.00			
Processing fee of \$		shing the English translated		\$				
					0.00	<u> </u>		
Fee for recording the end	TOTAL NATIONAL FEE = Fee for recording the enclosed assignment (37 CFR 1.21 (h)). Assignment				0.00	<u> </u>		
must be accompanied by appropriate cover sheet (37 CFR 3.28, 3.31) + (per property). +								
		TOTAL FEES E	NCLOSED =	\$	0.00			
				A	mount to be Refunded:	\$		
			i		Charged:	\$		
a. A check in the	amount of \$	to co	ver the above fees	is enclos	ed.			
b. Please charge my Deposit Account No. 03-1952 in the amount of \$ 0.00 to cover the above fees. A duplicate copy of this sheet is enclosed.								
c. X The Commissioner is hereby authorized to charge any additional fees which may be required or credit any overpayment to my Deposit Account No. 03-1952 A duplicate copy of this sheet is enclosed.								
d. Fees are to be charged to a credit card. Provide credit card information and authorization on PTO-2038.								
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137 (a) or (b)) must be filed and granted to restore the application to pending status.								
SEND ALL CORRESPONDENCE TO: Karen Babyak Dows								
Karen B. Dow SIGNATURE: MORRISON & FOERSTER LLP					Karen B. Dow			
3811 Valley Centre, Suite 500 NAME								
San Diego, California 92130 (858) 720-7960 REGISTRATION NU					29,684			
	MBER							

Attorney Docket No.: 280502000200

Certificate of Mailing Under 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to:

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

on	May 1, 2003	
	Date	Τ

Signature

Nora Durant

Typed or printed name of person signing Certificate

Note: Each paper must have its own certificate of mailing, or this certificate must identify each submitted paper.

Transmittal Letter to the United States Designated-Elected Office

CERTIFICATE OF MAILING BY "FIRST CLASS MAIL"

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Mail Stop DD Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on May 1, 2003.

Nora Durant

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In the application of:

Chaim M. ROIFMAN, et al.

Serial No.:

09/936,887

Filing Date:

September 11, 2001

METHODS AND COMPOSITIONS FOR

TREATING LEUKEMIA

Examiner: To be assigned

Group Art Unit: To be assigned

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. § 1.97

Mail Stop DD Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 C.F.R. § 1.97 and § 1.98, Applicants submit for consideration in the above-identified application the documents listed on the attached Form PTO-1449. Copies of the documents are also submitted herewith. The Examiner is requested to make these documents of record.

This application is a National Phase Application of International Patent Application Number PCT/CA00/00266, filed March 13, 2000, which claims the benefit of Canadian Patent Application Number 2,265,396, filed March 12, 1999.

This In	formati	ion Disclosure Statement is submitted:				
	With the application; accordingly, no fee or separate requirements are required.					
\boxtimes	Within three months of the application filing date or before mailing of a first Office					
	Action on the merits; accordingly, no fee or separate requirements are required.					
	After receipt of a first Office Action on the merits but before mailing of a final Office					
	Action or Notice of Allowance.					
		A fee is required. A check in the amount of * is enclosed.				
		A fee is required. Accordingly, a Fee Transmittal form (PTO/SB/17) is attached				
		to this submission in duplicate.				
		A Certification under 37 C.F.R. § 1.97(e) is provided below; accordingly; no fee				
		is believed to be due.				
	After r	mailing of a final Office Action or Notice of Allowance, but before payment of the				
	issue fee.					
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a check in the				
		amount of * is enclosed.				
		A Certification under 37 C.F.R. § 1.97(e) is provided below and a Fee Transmittal				
		form (PTO/SB/17 is attached to this submission in duplicate.				

Applicants would appreciate the Examiner initialing and returning the Form PTO-1449, indicating that the information has been considered and made of record herein.

The information contained in this Information Disclosure Statement under 37 C.F.R. § 1.97 is not to be construed as a representation that: (i) a complete search has been made; (ii) additional information material to the examination of this application does not exist; (iii) the information, protocols, results and the like reported by third parties are accurate or enabling; or (iv) the above information constitutes prior art to the subject invention.

In the unlikely event that the transmittal letter is separated from this document and the Patent Office determines that an extension and/or other relief is required, applicant petitions for any required relief including extensions of time and authorizes the Assistant Commissioner to charge the cost of such petitions and/or other fees due in connection with the filing of this document to **Deposit Account No. 03-1952** referencing 280502000200. However, the Assistant Commissioner is not authorized to charge the cost of the issue fee to the Deposit Account.

Dated: May 1, 2003

Respectfully submitted,

Registration No. 29,684

Morrison & Foerster LLP 3811 Valley Centre Drive

Suite 500

San Diego, California 92130-2332

Telephone: (858) 720-7960 Facsimile: (858) 720-5125

,					Daglest Number 2005	02000200	Application Nu		eet 1 of 1	
Form PTO-1449				L	Docket Number 280502000200 Application Number 09/936,887					
INFORMATION DISCLOSURE CITATION IN AN APPLICATION					Applicant Chaim M. ROIFMAN, et al.					
		se several sheets if			Filing Date September	Group Art Unit To be assigned				
					Mailing Date May 1, 2003					
			·	TENT	DOCUMENT			~~~		
Examiner Initials	Ref. No.	Date	Document No.		Name Clas				Filing Date If Appropriate	
	1.	06/1993	5,217,999	Levit	zki et al.					
	2.	06/1998	5,773,476	Chen	et al.			•		
Examiner Ref. Date Document No.			NT DOCUME Country	Class	Subclass	Trans YES	lation NO			
Initials	No.	11/1994	WO 94/26260	WIPO				110		
Examiner	Ref.	Title	OTHE	R DO	CUMENTS	(includi	ng author, title, Da	te, Pertinent i	Pages, Etc.)	
Initials	No. 4.	Gozit et al	t et al., J. Med. Chem. (1991) 34:1896-1907							
	5.		J. Med. Chem. (1993		· · · · · · · · · · · · · · · · · · ·					
		Gazit et al.,	J. Med. Chem. (1993	90:33						
EXAMINER:					DATE CO	NSIDERED:				
			sidered, whether or not the				line through the	citation if no	ot in	